Terazosin Hydrochloride

HCID 63016CAS 70024-40-7

基本情報

標準SMILES: COc1cc2nc(N3CCN(C(=O)C4CCCO4)CC3)nc(N)c2cc1OC.Cl.O.O
InChIKey: NZMOFYDMGFQZLS-UHFFFAOYSA-N
分子式: C19H30ClN5O6
平均分子量: 459.9 g/mol
単同位体質量: 459.18846136

概要

Terazosin Hydrochloride is the hydrochloride salt form of terazosin, a quinazoline derivative with adrenergic antagonistic property. Terazosin hydrochloride selectively inhibits alpha-1 adrenergic receptors, resulting in vasodilation leading to decreased peripheral vascular resistance and a reduced venous return to the heart as well as decreased urethral resistance, which potentially improving urine flow and symptoms related to benign prostatic hyperplasia. In addition, terazosin decreases low-density lipoproteins (LDL) and triglycerides while increasing the concentration of high-density lipoproteins (HDL).

名称と識別子

優先名称: Terazosin Hydrochloride
IUPAC: [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(oxolan-2-yl)methanone;dihydrate;hydrochloride

名称と別名

Terazosin hydrochloride dihydrateUrodieItrinHytracinAbbott-45975TEZRULYTerazosin hcl 2h20Terazosin (as hydrochloride)1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(tetrahydro-2-furoyl)piperazine monohydrochloride dihydrateD32S14F082NSC-759168Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-((tetrahydro-2-furanyl)carbonyl)-, monohydrochloride, dihydrate

名称をさらに表示

CHEBI:9446DTXCID5025493BenphRefChem:571796,7-dimethoxy-2-(4-(tetrahydrofuran-2-ylcarbonyl)piperazin-1-yl)quinazolin-4-amine hydrochloride dihydrateDTXSID7045493Terazosin Hydrochloride70024-40-7

データベース識別子

CAS: 70024-40-7
PubChem CID: 63016
DTXSID: DTXSID801366621
ChEMBL: CHEMBL1201091、CHEMBL3989562
UNII: D32S14F082

物性

構造計算による物性

極性表面積: 105 Å²
水素結合供与体数: 4
水素結合受容体数: 10
回転可能結合数: 4
重原子数: 31
形式電荷: 0
複雑度: 544

実験および物理化学的性質

Human Drugs · 2 件

FDA approved drugs -> Active ingredient

安全と法規制

毒性情報

Treatment · 1 件

Should overdosage of Terazosin lead to hypotension, support of the cardiovascular system is of first importance. Restoration of blood pressure and normalization of heart rate may be accomplished by keeping the patient in the supine position. If this measure is inadequate, shock should first be treated with volume expanders. If necessary, vasopressors should then be used and renal function should be monitored and supported as needed. Laboratory data indicate that Terazosin is highly protein bound; therefore, dialysis may not be of benefit. (L1712)

Health EffectsHypotension, palpitations, postural hypotension, syncope, peripheral edema, weight gain, dyspnea, nasal congestion/rhinitis, impotence.

Exposure RoutesOral. Essentially completely absorbed in man (90% bioavailability).

Toxicity Summary · 1 件

Terazosin selectively and competitively inhibits vascular postsynaptic alpha(1)-adrenergic receptors, resulting in peripheral vasodilation and a reduction of vascular resistance and blood pressure. Unlike the nonselective alph-adrenergic blockers phenoxybenzamine and phentolamine, terazosin does not block presynaptic alpha(2)-receptors and, hence, does not cause reflex activation of norepinephrine release to produce reflex tachycardia.

Signs and SymptomsAsthenia, postural hypotension, dizziness, somnolence, nasal congestion/rhinitis.

Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).

化学と産業

薬理情報

Metabolism/Metabolites · 1 件

Hepatic. One of the four metabolites identified (piperazine derivative of terazosin) has antihypertensive activity. Route of Elimination: Approximately 10% of an orally administered dose is excreted as parent drug in the urine and approximately 20% is excreted in the feces. Half Life: 12 hours

FDA Pharmacological Classification · 2 件

TERAZOSIN HYDROCHLORIDE

Adrenergic alpha-Antagonists [MoA]; alpha-Adrenergic Blocker [EPC]

MeSH Pharmacological Classification · 2 件

Drugs that bind to and block the activation of ADRENERGIC ALPHA-1 RECEPTORS.

Drugs used in the treatment of urological conditions and diseases such as URINARY INCONTINENCE and URINARY TRACT INFECTIONS.

用途と製造

Uses · 1 件

Terazosin is indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH). There is a rapid response, with approximately 70% of patients experiencing an increase in urinary flow and improvement in symptoms of BPH when treated with terazosin. The long-term effects of terazosin on the incidence of surgery, acute urinary obstruction or other complications of BPH are yet to be determined. Terazosin tablets are also indicated for the treatment of hypertension. Terazosin tablets can be used alone or in combination with other antihypertensive agents such as diuretics or beta-adrenergic blocking agents.